FDA Clears Prelude Therapeutics to Begin Phase 1 Trial of PRT13722 in HR+ Breast Cancer
PRLD has more than doubled off its 52-week low of $0.981.
Summary
Prelude Therapeutics received FDA clearance to begin a Phase 1 study of PRT13722, its first-in-class oral KAT6A selective degrader for HR+ breast cancer, with enrollment expected in Q4 2026. The filing includes an investor presentation with strong preclinical data and updated pipeline milestones.
Key Events · Product Development and Regulatory · PRLD
-
FDA Clears PRT13722 Phase 1
FDA cleared the IND for PRT13722, a first-in-class oral KAT6A selective degrader for HR+/HER2- breast cancer. Phase 1 enrollment expected to begin Q4 2026.
-
Strong Preclinical Data
PRT13722 shows >1,000x selectivity over KAT6B, 0.3 nM DC50 potency, and 100% complete response rate in treatment-refractory PDX models — outperforming Pfizer's prifetrastat in head-to-head preclinical studies.
-
Large Market Opportunity
Company estimates $40B+ total addressable market (US/EU5) for HR+ breast cancer, with $5-10B+ potential peak sales for advanced disease alone.
-
Phase 1 Design
Open-label, multicenter study evaluating monotherapy and combinations with fulvestrant, CDK4/6 inhibitors, and oral SERDs. Key data readouts expected 2027/2028.
Analysis · PRLD · Life Sciences
A key pipeline milestone for Prelude: FDA clearance to begin Phase 1 for PRT13722, a first-in-class oral KAT6A selective degrader. The accompanying investor presentation reveals compelling preclinical data — >1,000x selectivity over KAT6B, sub-nanomolar potency, and 100% complete responses in treatment-refractory PDX models — positioning PRT13722 as a potential backbone therapy in a $40B+ HR+ breast cancer market. Enrollment is expected to begin in Q4 2026, with initial data readouts in 2027/2028. This comes on the heels of the company's Q2 report showing cash runway into 2028, giving the program adequate funding to reach key data milestones.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30.2% of the 2009 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PRLD was trading at $5.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $406.2M. The 52-week trading range was $0.98 to $6.83. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.